A staff member checks a COVID-19 vaccine package in Beijing. China has approved Sinopharm’s vaccine after clinical trials showed it has a 79% efficacy against COVID-19.

BEIJING, Dec. 25, 2020 — A staff member checks the packaging quality of COVID-19 inactivated vaccine products at a packaging plant of the Beijing Biological Products Institute Co., Ltd. in Beijing, capital of China, Dec. 25, 2020. A Chinese inactivated vaccine shows 79.34 percent efficacy against COVID-19, according to the interim results of the phase-3 clinical trials unveiled by its developer Wednesday. The inactivated vaccine is developed by the Beijing Biological Products Institute Co., Ltd. under the China National Biotec Group CNBG, which is affiliated with Sinopharm. After a two-dose inoculation procedure, the vaccine receivers all produced high titers of antibodies, and the seroconversion rate of neutralizing antibodies reached 99.52 percent. The results meet the requirements of technical standards of the World Health Organization and the standards stipulated by China’s National Medical Products Administration NMPA. The company has submitted an application to the NMPA for conditioned market approval. (Photo by Zhang Yuwei/Xinhua via Getty) (Xinhua/Zhang Yuwei via Getty Images)